279 related articles for article (PubMed ID: 25245375)
21. Epidermal Growth Factor Receptor Tyrosine Kinase: A Potential Target in Treatment of Non-Small-Cell Lung Carcinoma.
Prabhu VV; Devaraj N
J Environ Pathol Toxicol Oncol; 2017; 36(2):151-158. PubMed ID: 29199595
[TBL] [Abstract][Full Text] [Related]
22. Afatinib: a second-generation EGF receptor and ErbB tyrosine kinase inhibitor for the treatment of advanced non-small-cell lung cancer.
Marquez-Medina D; Popat S
Future Oncol; 2015 Sep; 11(18):2525-40. PubMed ID: 26314834
[TBL] [Abstract][Full Text] [Related]
23. Peptides for Dual Targeting of ErbB1 and ErbB2: Blocking EGFR Cell Signaling Transduction Pathways for Cancer Chemotherapy.
Patnaik SK; Swaroop AK; Nagarjuna P; Nanjan MJ; Chandrasekar MJN
Curr Mol Pharmacol; 2024; 17(1):e240223214012. PubMed ID: 36843255
[TBL] [Abstract][Full Text] [Related]
24. ErbB Receptors and Cancer.
Wang Z
Methods Mol Biol; 2017; 1652():3-35. PubMed ID: 28791631
[TBL] [Abstract][Full Text] [Related]
25. ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors.
Roskoski R
Pharmacol Res; 2014 Sep; 87():42-59. PubMed ID: 24928736
[TBL] [Abstract][Full Text] [Related]
26. Small Molecule EGFR Inhibitors as Anti-Cancer Agents: Discovery, Mechanisms of Action, and Opportunities.
Zubair T; Bandyopadhyay D
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768973
[TBL] [Abstract][Full Text] [Related]
27. Emerging treatments in oncology: focus on tyrosine kinase (erbB) receptor inhibitors.
Hamid O
J Am Pharm Assoc (2003); 2004; 44(1):52-8. PubMed ID: 14965154
[TBL] [Abstract][Full Text] [Related]
28. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
29. HER family inhibitors in pancreatic cancer: current status and future directions.
Berz D; Miner T; McCormack E; Safran H
Expert Opin Ther Targets; 2007 Mar; 11(3):337-47. PubMed ID: 17298292
[TBL] [Abstract][Full Text] [Related]
30. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020.
Liang X; Yang Q; Wu P; He C; Yin L; Xu F; Yin Z; Yue G; Zou Y; Li L; Song X; Lv C; Zhang W; Jing B
Bioorg Chem; 2021 Aug; 113():105011. PubMed ID: 34091289
[TBL] [Abstract][Full Text] [Related]
31. HER family in cancer progression: From discovery to 2020 and beyond.
Kumar R; George B; Campbell MR; Verma N; Paul AM; Melo-Alvim C; Ribeiro L; Pillai MR; da Costa LM; Moasser MM
Adv Cancer Res; 2020; 147():109-160. PubMed ID: 32593399
[TBL] [Abstract][Full Text] [Related]
32. EGFRIndb: epidermal growth factor receptor inhibitor database.
Yadav IS; Singh H; Khan MI; Chaudhury A; Raghava GP; Agarwal SM
Anticancer Agents Med Chem; 2014; 14(7):928-35. PubMed ID: 24661111
[TBL] [Abstract][Full Text] [Related]
33. Epidermal growth factor receptor: Structure-function informing the design of anticancer therapeutics.
Mitchell RA; Luwor RB; Burgess AW
Exp Cell Res; 2018 Oct; 371(1):1-19. PubMed ID: 30098332
[TBL] [Abstract][Full Text] [Related]
34. [A new perspective in the treatment of non-small-cell lung cancer (NSCLC). Role of afatinib: An oral and irreversible ErbB family blocker].
Wislez M; Malka D; Bennouna J; Mortier L; Bensadoun RJ; Sicard J; Dielenseger P; Rey JB; Moro-Sibilot D; Scotté F
Bull Cancer; 2014 Jun; 101(6):647-52. PubMed ID: 24977454
[TBL] [Abstract][Full Text] [Related]
35. Targeting the HER-kinase axis in cancer.
Gross ME; Shazer RL; Agus DB
Semin Oncol; 2004 Feb; 31(1 Suppl 3):9-20. PubMed ID: 15052539
[TBL] [Abstract][Full Text] [Related]
36. Novel substituted quinazolines for potent EGFR tyrosine kinase inhibitors.
Cruz-López O; Conejo-García A; Núñez MC; Kimatrai M; García-Rubiño ME; Morales F; Gómez-Pérez V; Campos JM
Curr Med Chem; 2011; 18(7):943-63. PubMed ID: 21254978
[TBL] [Abstract][Full Text] [Related]
37. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors from the natural origin: a recent perspective.
Patel HM; Rane R; Thapliyal N; Palkar M; Shaikh M; Karpoormath R
Anticancer Agents Med Chem; 2015; 15(8):988-1011. PubMed ID: 25763933
[TBL] [Abstract][Full Text] [Related]
38. ErbB receptor tyrosine kinase inhibitors as therapeutic agents.
Anderson NG; Ahmad T
Front Biosci; 2002 Sep; 7():d1926-40. PubMed ID: 12161338
[TBL] [Abstract][Full Text] [Related]
39. How to train your inhibitor: Design strategies to overcome resistance to Epidermal Growth Factor Receptor inhibitors.
Milik SN; Lasheen DS; Serya RAT; Abouzid KAM
Eur J Med Chem; 2017 Dec; 142():131-151. PubMed ID: 28754471
[TBL] [Abstract][Full Text] [Related]
40. New Molecular Targets of Anticancer Therapy - Current Status and Perspectives.
Zajac M; Muszalska I; Jelinska A
Curr Med Chem; 2016; 23(37):4176-4220. PubMed ID: 27528054
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
